Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALYCENDO: ASA Effects on Immunoparalysis
NCT02922673Completed
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2016
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of aspirin in sepsis (3 arms), sponsored by Radboud University Medical Center. Primary endpoint: Change in concentration plasma TNFalpha at Day 14. Started Sep 2016; status: completed.
02
Drugs
aspirin
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT02922673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02922673.